Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐Reperfusion
BackgroundCardiomyocyte‐specific transgenic mice overexpressing S100A6, a member of the family of EF‐hand calcium‐binding proteins, develop less cardiac hypertrophy, interstitial fibrosis, and myocyte apoptosis after permanent coronary ligation, findings that support S100A6 as a potential therapeuti...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-02-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.116.004738 |
| _version_ | 1818289522394267648 |
|---|---|
| author | Azadeh Mofid Nadav S. Newman Paul J. H. Lee Cynthia Abbasi Pratiek N. Matkar Dmitriy Rudenko Michael A. Kuliszewski Hao H. Chen Kolsoom Afrasiabi James N. Tsoporis Anthony O. Gramolini Kim A. Connelly Thomas G. Parker Howard Leong‐Poi |
| author_facet | Azadeh Mofid Nadav S. Newman Paul J. H. Lee Cynthia Abbasi Pratiek N. Matkar Dmitriy Rudenko Michael A. Kuliszewski Hao H. Chen Kolsoom Afrasiabi James N. Tsoporis Anthony O. Gramolini Kim A. Connelly Thomas G. Parker Howard Leong‐Poi |
| author_sort | Azadeh Mofid |
| collection | DOAJ |
| description | BackgroundCardiomyocyte‐specific transgenic mice overexpressing S100A6, a member of the family of EF‐hand calcium‐binding proteins, develop less cardiac hypertrophy, interstitial fibrosis, and myocyte apoptosis after permanent coronary ligation, findings that support S100A6 as a potential therapeutic target after acute myocardial infarction. Our purpose was to investigate S100A6 gene therapy for acute myocardial ischemia‐reperfusion. Methods and ResultsWe first performed in vitro studies to examine the effects of S100A6 overexpression and knockdown in rat neonatal cardiomyocytes. S100A6 overexpression improved calcium transients and protected against apoptosis induced by hypoxia‐reoxygenation via enhanced calcineurin activity, whereas knockdown of S100A6 had detrimental effects. For in vivo studies, human S100A6 plasmid or empty plasmid was delivered to the left ventricular myocardium by ultrasound‐targeted microbubble destruction in Fischer‐344 rats 2 days prior to a 30‐minute ligation of the left anterior descending coronary artery followed by reperfusion. Control animals received no therapy. Pretreatment with S100A6 gene therapy yielded a survival advantage compared to empty‐plasmid and nontreated controls. S100A6‐pretreated animals had reduced infarct size and improved left ventricular systolic function, with less myocyte apoptosis, attenuated cardiac hypertrophy, and less cardiac fibrosis. ConclusionsS100A6 overexpression by ultrasound‐targeted microbubble destruction helps ameliorate myocardial ischemia‐reperfusion, resulting in lower mortality and improved left ventricular systolic function post–ischemia‐reperfusion via attenuation of apoptosis, reduction in cardiac hypertrophy, and reduced infarct size. Our results indicate that S100A6 is a potential therapeutic target for acute myocardial infarction. |
| first_indexed | 2024-12-13T02:13:37Z |
| format | Article |
| id | doaj.art-92df0ac64eb74894904427e941a361fd |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-12-13T02:13:37Z |
| publishDate | 2017-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-92df0ac64eb74894904427e941a361fd2022-12-22T00:02:57ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802017-02-016210.1161/JAHA.116.004738Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐ReperfusionAzadeh Mofid0Nadav S. Newman1Paul J. H. Lee2Cynthia Abbasi3Pratiek N. Matkar4Dmitriy Rudenko5Michael A. Kuliszewski6Hao H. Chen7Kolsoom Afrasiabi8James N. Tsoporis9Anthony O. Gramolini10Kim A. Connelly11Thomas G. Parker12Howard Leong‐Poi13Division of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDepartment of Physiology, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDepartment of Physiology, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaDivision of Cardiology, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, CanadaBackgroundCardiomyocyte‐specific transgenic mice overexpressing S100A6, a member of the family of EF‐hand calcium‐binding proteins, develop less cardiac hypertrophy, interstitial fibrosis, and myocyte apoptosis after permanent coronary ligation, findings that support S100A6 as a potential therapeutic target after acute myocardial infarction. Our purpose was to investigate S100A6 gene therapy for acute myocardial ischemia‐reperfusion. Methods and ResultsWe first performed in vitro studies to examine the effects of S100A6 overexpression and knockdown in rat neonatal cardiomyocytes. S100A6 overexpression improved calcium transients and protected against apoptosis induced by hypoxia‐reoxygenation via enhanced calcineurin activity, whereas knockdown of S100A6 had detrimental effects. For in vivo studies, human S100A6 plasmid or empty plasmid was delivered to the left ventricular myocardium by ultrasound‐targeted microbubble destruction in Fischer‐344 rats 2 days prior to a 30‐minute ligation of the left anterior descending coronary artery followed by reperfusion. Control animals received no therapy. Pretreatment with S100A6 gene therapy yielded a survival advantage compared to empty‐plasmid and nontreated controls. S100A6‐pretreated animals had reduced infarct size and improved left ventricular systolic function, with less myocyte apoptosis, attenuated cardiac hypertrophy, and less cardiac fibrosis. ConclusionsS100A6 overexpression by ultrasound‐targeted microbubble destruction helps ameliorate myocardial ischemia‐reperfusion, resulting in lower mortality and improved left ventricular systolic function post–ischemia‐reperfusion via attenuation of apoptosis, reduction in cardiac hypertrophy, and reduced infarct size. Our results indicate that S100A6 is a potential therapeutic target for acute myocardial infarction.https://www.ahajournals.org/doi/10.1161/JAHA.116.004738apoptosisgene therapyhypertrophyischemia‐reperfusionS100A6ultrasound‐targeted microbubble destruction |
| spellingShingle | Azadeh Mofid Nadav S. Newman Paul J. H. Lee Cynthia Abbasi Pratiek N. Matkar Dmitriy Rudenko Michael A. Kuliszewski Hao H. Chen Kolsoom Afrasiabi James N. Tsoporis Anthony O. Gramolini Kim A. Connelly Thomas G. Parker Howard Leong‐Poi Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐Reperfusion Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease apoptosis gene therapy hypertrophy ischemia‐reperfusion S100A6 ultrasound‐targeted microbubble destruction |
| title | Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐Reperfusion |
| title_full | Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐Reperfusion |
| title_fullStr | Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐Reperfusion |
| title_full_unstemmed | Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐Reperfusion |
| title_short | Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐Reperfusion |
| title_sort | cardiac overexpression of s100a6 attenuates cardiomyocyte apoptosis and reduces infarct size after myocardial ischemia reperfusion |
| topic | apoptosis gene therapy hypertrophy ischemia‐reperfusion S100A6 ultrasound‐targeted microbubble destruction |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.116.004738 |
| work_keys_str_mv | AT azadehmofid cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT nadavsnewman cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT pauljhlee cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT cynthiaabbasi cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT pratieknmatkar cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT dmitriyrudenko cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT michaelakuliszewski cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT haohchen cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT kolsoomafrasiabi cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT jamesntsoporis cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT anthonyogramolini cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT kimaconnelly cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT thomasgparker cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion AT howardleongpoi cardiacoverexpressionofs100a6attenuatescardiomyocyteapoptosisandreducesinfarctsizeaftermyocardialischemiareperfusion |